Inflammatory Bowel Diseases

Papers
(The H4-Index of Inflammatory Bowel Diseases is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
INFLAMMATORY BOWEL DISEASE IN APPALACHIA: AN INVESTIGATION INTO DISPARATE OUTCOMES WITHIN THE STATE OF KENTUCKY123
THE ROLE OF GROUP 3 INNATE LYMPHOID CELLS (ILC3) IN GM-CSF/CSF2RB-DEPENDENT INTESTINAL HOMEOSTASIS IN CROHN’S DISEASE67
UPADACITINIB AS SECOND- AND THIRD-LINE SALVAGE THERAPY FOR REFRACTORY ACUTE SEVERE ULCERATIVE COLITIS60
GENETIC OVERLAP BETWEEN INFLAMMATORY BOWEL DISEASE AND PARKINSON’S DISEASE IMPLICATES THE ROLE OF ADAPTIVE IMMUNE RESPONSE IN THEIR COMORBIDITY58
LMT503, A NOVEL THERAPY FOR INFLAMMATORY BOWEL DISEASE THROUGH MACROPHAGE POLARIZATIONS BY METABOLIC REPROGRAMMING OF ACTIVATED MACROPHAGE57
POINT-OF-CARE INTESTINAL ULTRASOUND FOR THE DETECTION OF POSTOPERATIVE CROHN’S DISEASE ENDOSCOPIC RECURRENCE53
NIPEP-IBD; A SYNTHETIC PEPTIDE TARGETING NOVEL MOLECULE, INTEGRIN BETA 1, TO RESTITUTE INTESTINAL EPITHELIAL CELLS FOR INFLAMMATORY BOWEL DISEASE (IBD) TREATMENT52
SECURE ELECTRONIC DOCUMENT SIGNING UPTAKE IN BIOLOGIC PRESCRIBING FOR IMMUNE MEDIATED DISEASES48
MICROSCOPIC COLITIS IS ASSOCIATED WITH DECREASED BONE DENSITY: A SYSTEMATIC REVIEW AND META-ANALYSIS43
CHRONIC COLITIS ALTERS BRAIN ACTIVITY BY INDUCING HMGB1-MEDIATED PYROPTOSIS IN MICE42
IDENTIFYING THE MOST EFFECTIVE TREATMENT ALGORITHM FOR THERAPIES TO TREAT MODERATE TO SEVERE ULCERATIVE COLITIS38
Reply: MIND the Gap: Psychiatric Conditions in Inflammatory Bowel Disease36
Postoperative Crohn’s Disease Recurrence Risk and Optimal Biologic Timing After Temporary Diversion Following Ileocolic Resection36
Pan-enteric Capsule Endoscopy to Characterize Crohn’s Disease Phenotypes and Predict Clinical Outcomes in Children and Adults: The Bomiro Study35
Prospective Evaluation of the Prediction Score for a Mild Course of Crohn’s Disease (PreMiCC) in Newly Diagnosed Patients With Crohn’s Disease: The PROGNOS Study35
Letter to the Editors35
GUT-ASSOCIATED LYMPHOID TISSUE ATTRITION ASSOCIATES WITH RESPONSE TO ANTI-α4β7 THERAPY IN ULCERATIVE COLITIS34
CHARACTERIZING STROMAL-EPITHELIAL INTERACTIONS IN INTESTINAL STRICTURES34
THIRTY YEAR EXPERIENCE WITH BARNETT CONTINENT INTESTINAL RESERVOIR: A SINGLE INSTITUTION’S EXPERIENCE34
TRENDS AND DISPARITIES IN THE BURDEN OF INFLAMMATORY BOWEL DISEASE IN MISSOURI OVER THREE DECADES34
Increasing Exposure to Inflammatory Bowel Diseases Education in Gastroenterology Fellowship: The Pilot IBD 101 Experience34
ESTABLISHING CLINICAL C-REACTIVE PROTEIN LEVELS IN SWEAT BASED WEARABLES FOR INFLAMMATORY BOWEL DISEASE SUBJECTS WITH ULCERATIVE COLITIS33
EFFICACY AND SAFETY OF UPADACITINIB FOR ACUTE SEVERE ULCERATIVE COLITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS32
LOCAL INFLAMMATION IMPRINTS AN UNRESTRAINED TISSUE-ADAPTED PHENOTYPE ON INTESTINAL EOSINOPHILS32
CARDIAC MANIFESTATIONS OF MESALAMINE USE IN INFLAMMATORY BOWEL DISEASE: CASE REPORT AND REVIEW OF THE LITERATURE30
COMPARATIVE EFFICACY OF VEDOLIZUMAB VERSUS USTEKINUMAB IN UC PATIENTS AFTER ANTI-TNF THERAPY FAILURE: A SYSTEMATIC REVIEW AND META-ANALYSIS29
DELAYS IN THE ADMINISTRATION OF BIOLOGIC THERAPIES AND ADVERSE OUTCOMES IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A RETROSPECTIVE STUDY29
COMPARATIVE EFFECTIVENESS OF ORAL JANUS KINASE INHIBITORS VERSUS VEDOLIZUMAB IN ULCERATIVE COLITIS AFTER ANTI-TNF THERAPY FAILURE: A SYSTEMATIC REVIEW AND META-ANALYSIS29
IL-23-ACTIVATED CELLS PREDICT RESPONSE TO RISANKIZUMAB IN CROHN’S DISEASE29
PATIENT ATTITUDES TO MAGNETIC RESONANCE IMAGING IN PERIANAL FISTULIZING CROHNS DISEASE: A GLOBAL SURVEY29
0.029762983322144